Evidence map›Paper›PMID 40450653›Full record

ArticleCEN case reports2025

An end-stage kidney disease patient undergoing dialysis treatment for 50 years with dialysis-related amyloidosis in multiple organs.

Toru Ito, Takashi Kato, Suguru Yamamoto, Hisaki Shimada, Hideyuki Kabasawa, Shin Goto, Riuko Ohashi, Ichiei Narita

Abstract readCase Reports
In one paragraph

Article in CEN case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Toru Ito *Division of Clinical Nephrology and Rheumatology, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan.
Takashi Kato *Divisions of Molecular and Diagnostic Pathology, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan.
Suguru YamamotoDivision of Clinical Nephrology and Rheumatology, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan. yamamots@med.niigata-u.ac.jp.ORCID 0000-0002-8279-2966
Hisaki ShimadaKidney Center of Shinraku-en Hospital, Niigata, Japan.
Hideyuki KabasawaDepartment of Clinical Nutrition Science, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan.
Shin GotoDivision of Clinical Nephrology and Rheumatology, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan.
Riuko OhashiDivisions of Molecular and Diagnostic Pathology, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan.
Ichiei NaritaDivision of Clinical Nephrology and Rheumatology, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Advancements in dialysis treatment have led to an increase in the number of patients undergoing long-term dialysis. These patients often experience a decline in activities of daily living (ADL) owing to various chronic kidney disease-related conditions such as mineral and bone disorders, dialysis-related amyloidosis (DRA), and cardiovascular diseases. A male patient began hemodialysis at the age of 22 years because of end-stage kidney disease caused by chronic glomerulonephritis and continued dialysis treatment for 50 years. The patient died at 72 years of age from sepsis, ischemic colitis, and pneumonia. During the course of treatment, the patient frequently underwent surgeries for carpal tunnel syndrome and destructive spondyloarthropathy, which led to a decline in ADL. An autopsy revealed β

Indexed as

AmyloidosisKidney Failure, ChronicRenal DialysisActivities of Daily LivingAgedbeta 2-MicroglobulinFatal OutcomeHumansMalebeta 2-MicroglobulinDialysis-related amyloidosisFrailtyLong-term dialysis treatmentβ2-microglobulin adsorption column

Identifiers

PMID40450653
PMCPMC12307826

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.